Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody

Gary R. Klimpel, Tonyia Eaves-Pyles, Scott T. Moen, Joanna Taormina, Johnny Peterson, Ashok Chopra, David Niesel, Paige Carness, Judith L. Haithcoat, Michelle Kirtley, Abdelhakim Ben Nasr

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The ability to protect mice against respiratory infections with virulent Francisella tularensis has been problematic and the role of antibody-versus-cell-mediated immunity controversial. In this study, we tested the hypothesis that protective immunity can develop in mice that were given antibiotic therapy following infection via the respiratory tract with F. tularensis SCHU S4. We show that mice infected with a lethal dose of SCHU S4, via an intra-nasal challenge, could be protected with levofloxacin treatment. This protection was evident even when levofloxacin treatment was delayed 72 h post-infection. At early time points after levofloxacin treatment, significant numbers of bacteria could be recovered from the lungs and spleens of mice, which was followed by a dramatic disappearance of bacteria from these tissues. Mice successfully treated with levofloxacin were later shown to be almost completely resistant to re-challenge with SCHU S4 by the intra-nasal route. Serum antibody appeared to play an important role in this immunity. Normal mice, when given sera from animals protected by levofloxacin treatment, were solidly protected from a lethal intra-nasal challenge with SCHU S4. The protective antiserum contained high titers of SCHU S4-specific IgG2a, indicating that a strong Th1 response was induced following levofloxacin treatment. Thus, this study describes a potentially valuable animal model for furthering our understanding of respiratory tularemia and provides suggestive evidence that antibody can protect against respiratory infections with virulent F. tularensis.

Original languageEnglish (US)
Pages (from-to)6874-6882
Number of pages9
JournalVaccine
Volume26
Issue number52
DOIs
StatePublished - Dec 9 2008

Fingerprint

Francisella tularensis
Levofloxacin
Nose
Antibody Formation
Immunity
immunity
antibodies
mice
Infection
Respiratory Tract Infections
infection
blood serum
Antibodies
tularemia
Bacteria
Tularemia
bacteria
lethal dose
Serum
Cellular Immunity

Keywords

  • Antibody
  • Bioweapon zoonosis
  • Francisella
  • Humoral immune response
  • Immunoglobulins
  • Lung
  • Quinolone
  • Tularemia
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. / Klimpel, Gary R.; Eaves-Pyles, Tonyia; Moen, Scott T.; Taormina, Joanna; Peterson, Johnny; Chopra, Ashok; Niesel, David; Carness, Paige; Haithcoat, Judith L.; Kirtley, Michelle; Nasr, Abdelhakim Ben.

In: Vaccine, Vol. 26, No. 52, 09.12.2008, p. 6874-6882.

Research output: Contribution to journalArticle

Klimpel, Gary R. ; Eaves-Pyles, Tonyia ; Moen, Scott T. ; Taormina, Joanna ; Peterson, Johnny ; Chopra, Ashok ; Niesel, David ; Carness, Paige ; Haithcoat, Judith L. ; Kirtley, Michelle ; Nasr, Abdelhakim Ben. / Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody. In: Vaccine. 2008 ; Vol. 26, No. 52. pp. 6874-6882.
@article{94698fd68eba46979e4aa21ead4f8c40,
title = "Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody",
abstract = "The ability to protect mice against respiratory infections with virulent Francisella tularensis has been problematic and the role of antibody-versus-cell-mediated immunity controversial. In this study, we tested the hypothesis that protective immunity can develop in mice that were given antibiotic therapy following infection via the respiratory tract with F. tularensis SCHU S4. We show that mice infected with a lethal dose of SCHU S4, via an intra-nasal challenge, could be protected with levofloxacin treatment. This protection was evident even when levofloxacin treatment was delayed 72 h post-infection. At early time points after levofloxacin treatment, significant numbers of bacteria could be recovered from the lungs and spleens of mice, which was followed by a dramatic disappearance of bacteria from these tissues. Mice successfully treated with levofloxacin were later shown to be almost completely resistant to re-challenge with SCHU S4 by the intra-nasal route. Serum antibody appeared to play an important role in this immunity. Normal mice, when given sera from animals protected by levofloxacin treatment, were solidly protected from a lethal intra-nasal challenge with SCHU S4. The protective antiserum contained high titers of SCHU S4-specific IgG2a, indicating that a strong Th1 response was induced following levofloxacin treatment. Thus, this study describes a potentially valuable animal model for furthering our understanding of respiratory tularemia and provides suggestive evidence that antibody can protect against respiratory infections with virulent F. tularensis.",
keywords = "Antibody, Bioweapon zoonosis, Francisella, Humoral immune response, Immunoglobulins, Lung, Quinolone, Tularemia, Vaccine",
author = "Klimpel, {Gary R.} and Tonyia Eaves-Pyles and Moen, {Scott T.} and Joanna Taormina and Johnny Peterson and Ashok Chopra and David Niesel and Paige Carness and Haithcoat, {Judith L.} and Michelle Kirtley and Nasr, {Abdelhakim Ben}",
year = "2008",
month = "12",
day = "9",
doi = "10.1016/j.vaccine.2008.09.077",
language = "English (US)",
volume = "26",
pages = "6874--6882",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "52",

}

TY - JOUR

T1 - Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody

AU - Klimpel, Gary R.

AU - Eaves-Pyles, Tonyia

AU - Moen, Scott T.

AU - Taormina, Joanna

AU - Peterson, Johnny

AU - Chopra, Ashok

AU - Niesel, David

AU - Carness, Paige

AU - Haithcoat, Judith L.

AU - Kirtley, Michelle

AU - Nasr, Abdelhakim Ben

PY - 2008/12/9

Y1 - 2008/12/9

N2 - The ability to protect mice against respiratory infections with virulent Francisella tularensis has been problematic and the role of antibody-versus-cell-mediated immunity controversial. In this study, we tested the hypothesis that protective immunity can develop in mice that were given antibiotic therapy following infection via the respiratory tract with F. tularensis SCHU S4. We show that mice infected with a lethal dose of SCHU S4, via an intra-nasal challenge, could be protected with levofloxacin treatment. This protection was evident even when levofloxacin treatment was delayed 72 h post-infection. At early time points after levofloxacin treatment, significant numbers of bacteria could be recovered from the lungs and spleens of mice, which was followed by a dramatic disappearance of bacteria from these tissues. Mice successfully treated with levofloxacin were later shown to be almost completely resistant to re-challenge with SCHU S4 by the intra-nasal route. Serum antibody appeared to play an important role in this immunity. Normal mice, when given sera from animals protected by levofloxacin treatment, were solidly protected from a lethal intra-nasal challenge with SCHU S4. The protective antiserum contained high titers of SCHU S4-specific IgG2a, indicating that a strong Th1 response was induced following levofloxacin treatment. Thus, this study describes a potentially valuable animal model for furthering our understanding of respiratory tularemia and provides suggestive evidence that antibody can protect against respiratory infections with virulent F. tularensis.

AB - The ability to protect mice against respiratory infections with virulent Francisella tularensis has been problematic and the role of antibody-versus-cell-mediated immunity controversial. In this study, we tested the hypothesis that protective immunity can develop in mice that were given antibiotic therapy following infection via the respiratory tract with F. tularensis SCHU S4. We show that mice infected with a lethal dose of SCHU S4, via an intra-nasal challenge, could be protected with levofloxacin treatment. This protection was evident even when levofloxacin treatment was delayed 72 h post-infection. At early time points after levofloxacin treatment, significant numbers of bacteria could be recovered from the lungs and spleens of mice, which was followed by a dramatic disappearance of bacteria from these tissues. Mice successfully treated with levofloxacin were later shown to be almost completely resistant to re-challenge with SCHU S4 by the intra-nasal route. Serum antibody appeared to play an important role in this immunity. Normal mice, when given sera from animals protected by levofloxacin treatment, were solidly protected from a lethal intra-nasal challenge with SCHU S4. The protective antiserum contained high titers of SCHU S4-specific IgG2a, indicating that a strong Th1 response was induced following levofloxacin treatment. Thus, this study describes a potentially valuable animal model for furthering our understanding of respiratory tularemia and provides suggestive evidence that antibody can protect against respiratory infections with virulent F. tularensis.

KW - Antibody

KW - Bioweapon zoonosis

KW - Francisella

KW - Humoral immune response

KW - Immunoglobulins

KW - Lung

KW - Quinolone

KW - Tularemia

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=56649117447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56649117447&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.09.077

DO - 10.1016/j.vaccine.2008.09.077

M3 - Article

VL - 26

SP - 6874

EP - 6882

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 52

ER -